The UCLA Biomarker Reference Laboratory (UCLA-BRL) is designed to be a continuation and expansion of the established EDRN-funded UCLA Biomarker Validation Laboratory (BVL). Significantly, the UCLA BVL is highly successful having established numerous EDRN collaborations and constructed tissue microarray resources for EDRN investigators. Our goals are in close alignment with the mission of the EDRN and include: i) The utilization our diverse infrastructure and highly skilled personnel to test, evaluate, quantify, and optimize detection of biomarkers useful early stage tumor marker. To this end, we have established Scientific Centers that can test for biomarkers in tissue (full tissue sections or 'intelligent' high density tissue microarrays) and in fluids (by conventional ELISA and nanotech electrochemical chip). In addition, we have the resources to detect nucleic acids in body fluids as well as DNA modification and alterations in tissue, cells and/or fluids. ii) The development of new platforms and algorithms for biomarker detection and analysis. This includes the development and implementation, in conjunction with an industrial partner, of a high throughput nano-detection chip for measuring biomarkers in fluids, and in-house pioneering research on mining biomarker profiles using tissue microarrays. iii) The continuation of a program at UCLA that is highly professional and focused, yet at the same time flexible and cost-effective in order to meet the challenges of an evolving EDRN program. iv) A strong commitment to collaboration, teamwork, and sharing of resources and data with EDRN members in order to promote the goal of identifying clinically useful early detection biomarkers. The UCLA-BRL leadership is highly capable and enthusiastic, and strongly dedicated to the goals of the EDRN. Moreover, the UCLA-BRL has strong institutional support from the School of Medicine, Jonsson Comprehensive Cancer Center, the UCLA Lung Cancer SPORE, and the UCLA Prostate Cancer SPORE. ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Resource-Related Research Projects--Cooperative Agreements (U24)
Project #
2U24CA086366-06
Application #
6941527
Study Section
Special Emphasis Panel (ZCA1-SRRB-E (J3))
Program Officer
Kagan, Jacob
Project Start
2000-05-16
Project End
2010-02-28
Budget Start
2005-08-01
Budget End
2006-02-28
Support Year
6
Fiscal Year
2005
Total Cost
$613,916
Indirect Cost
Name
University of California Los Angeles
Department
Pathology
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Hamilton, Nalo; Austin, David; Márquez-Garbán, Diana et al. (2017) Receptors for Insulin-Like Growth Factor-2 and Androgens as Therapeutic Targets in Triple-Negative Breast Cancer. Int J Mol Sci 18:
Kiyohara, M H; Dillard, C; Tsui, J et al. (2017) EMP2 is a novel therapeutic target for endometrial cancer stem cells. Oncogene 36:5793-5807
Hong, Candice Sun; Graham, Nicholas A; Gu, Wen et al. (2016) MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4. Cell Rep 14:1590-1601
Ho, Melissa E; Quek, Sue-Ing; True, Lawrence D et al. (2016) Bladder cancer cells secrete while normal bladder cells express but do not secrete AGR2. Oncotarget 7:15747-56
Hamilton, Nalo; Márquez-Garbán, Diana; Mah, Vei et al. (2015) Biologic roles of estrogen receptor-? and insulin-like growth factor-2 in triple-negative breast cancer. Biomed Res Int 2015:925703
Alavi, Mohammed; Mah, Vei; Maresh, Erin L et al. (2015) High expression of AGR2 in lung cancer is predictive of poor survival. BMC Cancer 15:655
Tian, Yuan; Choi, Caitlin H; Li, Qing Kay et al. (2015) Overexpression of periostin in stroma positively associated with aggressive prostate cancer. PLoS One 10:e0121502
Hamilton, Nalo; Marquez-Garban, Diana; Mah, Vei H et al. (2015) Estrogen Receptor-? and the Insulin-Like Growth Factor Axis as Potential Therapeutic Targets for Triple-Negative Breast Cancer. Crit Rev Oncog 20:373-90
Tang, Jason H; Chia, David (2015) Liquid Biopsies in the Screening of Oncogenic Mutations in NSCLC and its Application in Targeted Therapy. Crit Rev Oncog 20:357-71
Mah, Vei; Alavi, Mohammad; Márquez-Garbán, Diana C et al. (2015) Ribonucleotide reductase subunit M2 predicts survival in subgroups of patients with non-small cell lung carcinoma: effects of gender and smoking status. PLoS One 10:e0127600

Showing the most recent 10 out of 45 publications